Review



imaging chambers  (World Precision Instruments)


Bioz Verified Symbol World Precision Instruments is a verified supplier
Bioz Manufacturer Symbol World Precision Instruments manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    World Precision Instruments imaging chambers
    Imaging Chambers, supplied by World Precision Instruments, used in various techniques. Bioz Stars score: 96/100, based on 303 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imaging chambers/product/World Precision Instruments
    Average 96 stars, based on 303 article reviews
    imaging chambers - by Bioz Stars, 2026-05
    96/100 stars

    Images



    Similar Products

    imaging chambers  (World Precision Instruments)
    96
    World Precision Instruments imaging chambers
    Imaging Chambers, supplied by World Precision Instruments, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imaging chambers/product/World Precision Instruments
    Average 96 stars, based on 1 article reviews
    imaging chambers - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    incucyte live imaging chamber  (Sartorius AG)
    99
    Sartorius AG incucyte live imaging chamber
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Incucyte Live Imaging Chamber, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/incucyte live imaging chamber/product/Sartorius AG
    Average 99 stars, based on 1 article reviews
    incucyte live imaging chamber - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    spherical 3d printed soccer ball shaped imaging chamber  (Basler)
    95
    Basler spherical 3d printed soccer ball shaped imaging chamber
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Spherical 3d Printed Soccer Ball Shaped Imaging Chamber, supplied by Basler, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/spherical 3d printed soccer ball shaped imaging chamber/product/Basler
    Average 95 stars, based on 1 article reviews
    spherical 3d printed soccer ball shaped imaging chamber - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    temperature controlled delta t imaging chamber  (Bioptechs inc)
    95
    Bioptechs inc temperature controlled delta t imaging chamber
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Temperature Controlled Delta T Imaging Chamber, supplied by Bioptechs inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/temperature controlled delta t imaging chamber/product/Bioptechs inc
    Average 95 stars, based on 1 article reviews
    temperature controlled delta t imaging chamber - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    fcs2 imaging chamber  (Bioptechs inc)
    96
    Bioptechs inc fcs2 imaging chamber
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Fcs2 Imaging Chamber, supplied by Bioptechs inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fcs2 imaging chamber/product/Bioptechs inc
    Average 96 stars, based on 1 article reviews
    fcs2 imaging chamber - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    ivis spectrum ct in vivo imaging system chamber 284  (Revvity)
    96
    Revvity ivis spectrum ct in vivo imaging system chamber 284
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Ivis Spectrum Ct In Vivo Imaging System Chamber 284, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ivis spectrum ct in vivo imaging system chamber 284/product/Revvity
    Average 96 stars, based on 1 article reviews
    ivis spectrum ct in vivo imaging system chamber 284 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    imaging procedures  (Miltenyi Biotec)
    94
    Miltenyi Biotec imaging procedures
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Imaging Procedures, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/imaging procedures/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    imaging procedures - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    spectrum ct in vivo imaging system ivis chamber  (Revvity)
    96
    Revvity spectrum ct in vivo imaging system ivis chamber
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Spectrum Ct In Vivo Imaging System Ivis Chamber, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/spectrum ct in vivo imaging system ivis chamber/product/Revvity
    Average 96 stars, based on 1 article reviews
    spectrum ct in vivo imaging system ivis chamber - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    blot chamber  (Bio-Rad)
    99
    Bio-Rad blot chamber
    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an <t>IncuCyte</t> live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.
    Blot Chamber, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blot chamber/product/Bio-Rad
    Average 99 stars, based on 1 article reviews
    blot chamber - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an IncuCyte live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.

    Journal: Oncogene

    Article Title: EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2

    doi: 10.1038/s41388-025-03662-z

    Figure Lengend Snippet: A A panel of PCa cell lines (LNCaP, C4-2B, LNCaP95, 22Rv1, and VCaP) and a normal prostate epithelial cell line (RWPE) were treated with PROTAC-6272 and EPZ-6438 with increasing doses from nM to µM for 48 h, and half inhibitory concentrations (IC 50 ) of proliferation rates were assayed by cell Titer Glo ( n = 6). B A panel of PCa cell lines was treated with DMSO, PROTAC-6272 (1 µM), and EPZ-6438 (1 µM) and incubated in an IncuCyte live imager chamber; images were taken every 2 h up to 9 days. Cell proliferation rates were analyzed by IncuCyte live imager software ( n = 6). C 22Rv1 cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438 (1 µM). Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO. D VCaP cells were subjected to triplicate RNA-seq analysis upon 6 days of treatment with DMSO, PROTAC-6286, PROTAC-6272, and EPZ-6438. Heatmap shows combined differentially expressed genes identified ( | Log2FC | ≥0.585, adjusted p < 0.05) from treatment of PROTAC-6286, EPZ-6438, or PROTAC-6272 relative to DMSO.

    Article Snippet: For the Incucyte assay, cells were seeded in 96-well plates and allowed to stabilize for 24 h. Cells were then treated with 1 μM of DMSO, PROTAC-6272, and EPZ-6438 and incubated in the Incucyte live imaging chamber (Sartorius).

    Techniques: Incubation, Software, RNA Sequencing